A PHASE 1 STUDY OF CARFILZOMIB WITH RITUXIMAB, IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE (C‐RICE) IN TRANSPLANT‐ELIGIBLE RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
Gespeichert in:
| Veröffentlicht in: | Hematological oncology 2021-06, Vol.39 (S2) |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | S2 |
| container_start_page | |
| container_title | Hematological oncology |
| container_volume | 39 |
| creator | Torka, P. Groman, A. Wong, J. Baysal, B. Nichols, J. Kader, A. Mavis, C. Jani Sait, S. Block, A. Przespolewski, E. Mohr, A. Lund, I. McWhite, K. Kostrewa, J. DeMarco, J. Johnson, M. Darrall, A. Thomas, R.‐N. Sundaram, S. Ghione, P. Hutson, A. Hernandez‐Ilizaliturri, F. |
| description | |
| doi_str_mv | 10.1002/hon.83_2881 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2541701197</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2541701197</sourcerecordid><originalsourceid>FETCH-LOGICAL-c647-cd8e893a50a37b97144f1a7f9f1d641c5f896e7c3a71b5271ff04b336e425d273</originalsourceid><addsrcrecordid>eNotkc1O20AURkeISoS0q77ASN0UgWF-bI-9HNvjZKRxxhpPBGFjOY6tFkEc7LLoro_QB-GpeBImgtWV7nf03SsdAL5jdI0RIje_hv11RGsSRfgEzDCKYw-jMD4FM0RY5CFCyRk4n6YHhFyGohl45bBc8kpADCu7zjZQ5zDlJpfqXhcygbfSLqGRdn0nC55cQZnrKueFzMTVkUt0qbiVK8hXGRRWl7pyEfyZvv37b2QqLqDLrOGrynEr67ZCyYVMlIBGKF5WIrsxIjc8tdpsYCbzfO2eUdwsBEwcngqloNoU5VIX_Cv40jePU_ftc86BzYVNl57SC5ly5bWhz7x2F3VRTJsANZRtY4Z9v8cN6-Me70Ift0EfxWHHWtowvA0Iw32P_C2lYeeTYEcYnYMfH7WHcXh-6aY_9cPwMu7dxZoEPmYI4_hIXX5Q7ThM09j19WH8_dSMf2uM6qON2tmoP23Qd_d1ck0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2541701197</pqid></control><display><type>article</type><title>A PHASE 1 STUDY OF CARFILZOMIB WITH RITUXIMAB, IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE (C‐RICE) IN TRANSPLANT‐ELIGIBLE RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Torka, P. ; Groman, A. ; Wong, J. ; Baysal, B. ; Nichols, J. ; Kader, A. ; Mavis, C. ; Jani Sait, S. ; Block, A. ; Przespolewski, E. ; Mohr, A. ; Lund, I. ; McWhite, K. ; Kostrewa, J. ; DeMarco, J. ; Johnson, M. ; Darrall, A. ; Thomas, R.‐N. ; Sundaram, S. ; Ghione, P. ; Hutson, A. ; Hernandez‐Ilizaliturri, F.</creator><creatorcontrib>Torka, P. ; Groman, A. ; Wong, J. ; Baysal, B. ; Nichols, J. ; Kader, A. ; Mavis, C. ; Jani Sait, S. ; Block, A. ; Przespolewski, E. ; Mohr, A. ; Lund, I. ; McWhite, K. ; Kostrewa, J. ; DeMarco, J. ; Johnson, M. ; Darrall, A. ; Thomas, R.‐N. ; Sundaram, S. ; Ghione, P. ; Hutson, A. ; Hernandez‐Ilizaliturri, F.</creatorcontrib><identifier>ISSN: 0278-0232</identifier><identifier>EISSN: 1099-1069</identifier><identifier>DOI: 10.1002/hon.83_2881</identifier><language>eng</language><publisher>Chichester: Wiley Subscription Services, Inc</publisher><subject>B-cell lymphoma ; Carboplatin ; Etoposide ; Ifosfamide ; Immunotherapy ; Inhibitor drugs ; Lymphoma ; Monoclonal antibodies ; Rituximab ; Targeted cancer therapy</subject><ispartof>Hematological oncology, 2021-06, Vol.39 (S2)</ispartof><rights>2021 John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Torka, P.</creatorcontrib><creatorcontrib>Groman, A.</creatorcontrib><creatorcontrib>Wong, J.</creatorcontrib><creatorcontrib>Baysal, B.</creatorcontrib><creatorcontrib>Nichols, J.</creatorcontrib><creatorcontrib>Kader, A.</creatorcontrib><creatorcontrib>Mavis, C.</creatorcontrib><creatorcontrib>Jani Sait, S.</creatorcontrib><creatorcontrib>Block, A.</creatorcontrib><creatorcontrib>Przespolewski, E.</creatorcontrib><creatorcontrib>Mohr, A.</creatorcontrib><creatorcontrib>Lund, I.</creatorcontrib><creatorcontrib>McWhite, K.</creatorcontrib><creatorcontrib>Kostrewa, J.</creatorcontrib><creatorcontrib>DeMarco, J.</creatorcontrib><creatorcontrib>Johnson, M.</creatorcontrib><creatorcontrib>Darrall, A.</creatorcontrib><creatorcontrib>Thomas, R.‐N.</creatorcontrib><creatorcontrib>Sundaram, S.</creatorcontrib><creatorcontrib>Ghione, P.</creatorcontrib><creatorcontrib>Hutson, A.</creatorcontrib><creatorcontrib>Hernandez‐Ilizaliturri, F.</creatorcontrib><title>A PHASE 1 STUDY OF CARFILZOMIB WITH RITUXIMAB, IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE (C‐RICE) IN TRANSPLANT‐ELIGIBLE RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA</title><title>Hematological oncology</title><subject>B-cell lymphoma</subject><subject>Carboplatin</subject><subject>Etoposide</subject><subject>Ifosfamide</subject><subject>Immunotherapy</subject><subject>Inhibitor drugs</subject><subject>Lymphoma</subject><subject>Monoclonal antibodies</subject><subject>Rituximab</subject><subject>Targeted cancer therapy</subject><issn>0278-0232</issn><issn>1099-1069</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNotkc1O20AURkeISoS0q77ASN0UgWF-bI-9HNvjZKRxxhpPBGFjOY6tFkEc7LLoro_QB-GpeBImgtWV7nf03SsdAL5jdI0RIje_hv11RGsSRfgEzDCKYw-jMD4FM0RY5CFCyRk4n6YHhFyGohl45bBc8kpADCu7zjZQ5zDlJpfqXhcygbfSLqGRdn0nC55cQZnrKueFzMTVkUt0qbiVK8hXGRRWl7pyEfyZvv37b2QqLqDLrOGrynEr67ZCyYVMlIBGKF5WIrsxIjc8tdpsYCbzfO2eUdwsBEwcngqloNoU5VIX_Cv40jePU_ftc86BzYVNl57SC5ly5bWhz7x2F3VRTJsANZRtY4Z9v8cN6-Me70Ift0EfxWHHWtowvA0Iw32P_C2lYeeTYEcYnYMfH7WHcXh-6aY_9cPwMu7dxZoEPmYI4_hIXX5Q7ThM09j19WH8_dSMf2uM6qON2tmoP23Qd_d1ck0</recordid><startdate>202106</startdate><enddate>202106</enddate><creator>Torka, P.</creator><creator>Groman, A.</creator><creator>Wong, J.</creator><creator>Baysal, B.</creator><creator>Nichols, J.</creator><creator>Kader, A.</creator><creator>Mavis, C.</creator><creator>Jani Sait, S.</creator><creator>Block, A.</creator><creator>Przespolewski, E.</creator><creator>Mohr, A.</creator><creator>Lund, I.</creator><creator>McWhite, K.</creator><creator>Kostrewa, J.</creator><creator>DeMarco, J.</creator><creator>Johnson, M.</creator><creator>Darrall, A.</creator><creator>Thomas, R.‐N.</creator><creator>Sundaram, S.</creator><creator>Ghione, P.</creator><creator>Hutson, A.</creator><creator>Hernandez‐Ilizaliturri, F.</creator><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7QP</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>202106</creationdate><title>A PHASE 1 STUDY OF CARFILZOMIB WITH RITUXIMAB, IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE (C‐RICE) IN TRANSPLANT‐ELIGIBLE RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA</title><author>Torka, P. ; Groman, A. ; Wong, J. ; Baysal, B. ; Nichols, J. ; Kader, A. ; Mavis, C. ; Jani Sait, S. ; Block, A. ; Przespolewski, E. ; Mohr, A. ; Lund, I. ; McWhite, K. ; Kostrewa, J. ; DeMarco, J. ; Johnson, M. ; Darrall, A. ; Thomas, R.‐N. ; Sundaram, S. ; Ghione, P. ; Hutson, A. ; Hernandez‐Ilizaliturri, F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c647-cd8e893a50a37b97144f1a7f9f1d641c5f896e7c3a71b5271ff04b336e425d273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>B-cell lymphoma</topic><topic>Carboplatin</topic><topic>Etoposide</topic><topic>Ifosfamide</topic><topic>Immunotherapy</topic><topic>Inhibitor drugs</topic><topic>Lymphoma</topic><topic>Monoclonal antibodies</topic><topic>Rituximab</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Torka, P.</creatorcontrib><creatorcontrib>Groman, A.</creatorcontrib><creatorcontrib>Wong, J.</creatorcontrib><creatorcontrib>Baysal, B.</creatorcontrib><creatorcontrib>Nichols, J.</creatorcontrib><creatorcontrib>Kader, A.</creatorcontrib><creatorcontrib>Mavis, C.</creatorcontrib><creatorcontrib>Jani Sait, S.</creatorcontrib><creatorcontrib>Block, A.</creatorcontrib><creatorcontrib>Przespolewski, E.</creatorcontrib><creatorcontrib>Mohr, A.</creatorcontrib><creatorcontrib>Lund, I.</creatorcontrib><creatorcontrib>McWhite, K.</creatorcontrib><creatorcontrib>Kostrewa, J.</creatorcontrib><creatorcontrib>DeMarco, J.</creatorcontrib><creatorcontrib>Johnson, M.</creatorcontrib><creatorcontrib>Darrall, A.</creatorcontrib><creatorcontrib>Thomas, R.‐N.</creatorcontrib><creatorcontrib>Sundaram, S.</creatorcontrib><creatorcontrib>Ghione, P.</creatorcontrib><creatorcontrib>Hutson, A.</creatorcontrib><creatorcontrib>Hernandez‐Ilizaliturri, F.</creatorcontrib><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Hematological oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Torka, P.</au><au>Groman, A.</au><au>Wong, J.</au><au>Baysal, B.</au><au>Nichols, J.</au><au>Kader, A.</au><au>Mavis, C.</au><au>Jani Sait, S.</au><au>Block, A.</au><au>Przespolewski, E.</au><au>Mohr, A.</au><au>Lund, I.</au><au>McWhite, K.</au><au>Kostrewa, J.</au><au>DeMarco, J.</au><au>Johnson, M.</au><au>Darrall, A.</au><au>Thomas, R.‐N.</au><au>Sundaram, S.</au><au>Ghione, P.</au><au>Hutson, A.</au><au>Hernandez‐Ilizaliturri, F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A PHASE 1 STUDY OF CARFILZOMIB WITH RITUXIMAB, IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE (C‐RICE) IN TRANSPLANT‐ELIGIBLE RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA</atitle><jtitle>Hematological oncology</jtitle><date>2021-06</date><risdate>2021</risdate><volume>39</volume><issue>S2</issue><issn>0278-0232</issn><eissn>1099-1069</eissn><cop>Chichester</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1002/hon.83_2881</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-0232 |
| ispartof | Hematological oncology, 2021-06, Vol.39 (S2) |
| issn | 0278-0232 1099-1069 |
| language | eng |
| recordid | cdi_proquest_journals_2541701197 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | B-cell lymphoma Carboplatin Etoposide Ifosfamide Immunotherapy Inhibitor drugs Lymphoma Monoclonal antibodies Rituximab Targeted cancer therapy |
| title | A PHASE 1 STUDY OF CARFILZOMIB WITH RITUXIMAB, IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE (C‐RICE) IN TRANSPLANT‐ELIGIBLE RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T23%3A12%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20PHASE%201%20STUDY%20OF%20CARFILZOMIB%20WITH%20RITUXIMAB,%20IFOSFAMIDE,%20CARBOPLATIN%20AND%20ETOPOSIDE%20(C%E2%80%90RICE)%20IN%20TRANSPLANT%E2%80%90ELIGIBLE%20RELAPSED/REFRACTORY%20DIFFUSE%20LARGE%20B%E2%80%90CELL%20LYMPHOMA&rft.jtitle=Hematological%20oncology&rft.au=Torka,%20P.&rft.date=2021-06&rft.volume=39&rft.issue=S2&rft.issn=0278-0232&rft.eissn=1099-1069&rft_id=info:doi/10.1002/hon.83_2881&rft_dat=%3Cproquest_cross%3E2541701197%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2541701197&rft_id=info:pmid/&rfr_iscdi=true |